Phase 1 trial of QRL-201 to open for patients at sites across Europe
QurAlis soon expects to open its ongoing Phase 1 clinical trial testing QRL-201 in people with amyotrophic…
Articles by Andrea Lobo, PhD
Modulo Bio’s goal: Better understand and treat ALS, like diseases
Modulo Bio has launched with $8 million in funding and a goal to map the neuroimmune system and…
FDA final approval decision on NurOwn for ALS due by year’s end
A final decision by the U.S. Food and Drug Administration (FDA) on whether or not to approve NurOwn for…
Pegcetacoplan fails to improve ALS outcomes in MERIDIAN trial
Apellis Pharmaceuticals’ investigational therapy pegcetacoplan (APL-2) has failed to improve a combined assessment of function and survival in…
PARADIGM trial of PrimeC for ALS now fully enrolled with 69 adults
A Phase 2b trial of PrimeC for people with amyotrophic lateral sclerosis (ALS) has completed patient enrollment, according to…
First ALS patient dosed in Cellenkos’ trial of CK0803
Cellenkos has dosed the first patient in the Phase 1/1b clinical trial that’s evaluating its regulatory T-cell-based therapy CK0803…
PARADIGM trial of PrimeC in treating ALS nears full enrollment
A Phase 2b trial that’s testing PrimeC in people with amyotrophic lateral sclerosis (ALS) has reached 80% enrollment and…
Dosing begins in Phase 1 trial of QRL-201 in promoting neuronal repair
A first patient has been dosed in a Phase 1 clinical trial evaluating QRL-201, an experimental antisense oligonucleotide (ASO) molecule…
Collaboration to study PrimeC’s impacts on ALS disease mechanisms
NeuroSense Therapeutics has joined researchers at Massachusetts General Hospital to study the impact of its investigational therapy PrimeC on…
European approval of AMX0035 for ALS faces new hurdle in review
Amylyx Pharmaceuticals is facing a new hurdle — a second round of questions from a European Medicines Agency (EMA)…